Form 4: Vaxcyte CEO Grant Pickering Executes Stock Option and Sells Shares Under 10b5-1 Plan

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 23, 2024, Grant Pickering, CEO of Vaxcyte, Inc., exercised a stock option to acquire 15,000 shares of common stock at a price of $2.03 per share.
• Simultaneously, Pickering sold 5,718 shares at a weighted average price of $83.827 and 9,282 shares at a weighted average price of $84.528.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Pickering directly owns 478,888 shares of Vaxcyte common stock.
• Pickering also has indirect ownership of 143,438 shares held in a trust for his daughter and 143,438 shares held in a trust for his son.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity under a pre-arranged plan. The CEO is selling shares, but it's not necessarily indicative of a negative outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings provide transparency to the market.

Stakeholder Impact

• The stock sales by the CEO could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates